临床与病理杂志2018，Vol.38Issue(1)：167-174,8.DOI:10.3978/j.issn.2095-6959.2018.01.028
肺癌的免疫治疗
Immunotherapy of lung cancer
摘要
Abstract
In recent years, immunotherapy has become a new research direction of lung cancer. Immune checkpoint inhibitors (ICIs) including cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, programmed death-1 (PD-1) and its ligand (PD-Ll) inhibitors are becoming more and more important, which have achieved a success in the first-line or second-line treatment for non-small cell lung cancer.关键词
肺癌/免疫治疗/免疫检查点抑制药/疗效预测标志物/进展Key words
lung cancer/immunotherapy/immune checkpoint inhibitors/predictive marker/progression引用本文复制引用
陈东方..肺癌的免疫治疗[J].临床与病理杂志,2018,38(1):167-174,8.基金项目
上海市胸科医院科技发展基金重大重点项目(2014YZDC20700).This work was supported by Shanghai Chest Hospital Key Project, China (2014YZDC20700). （2014YZDC20700）
